According to a clinical study published in Obesity Pillars, participants taking the dietary supplement Calocurb lost an average of 8.3 pounds over 24 weeks while maintaining lean muscle mass. The findings arrive as consumers and researchers increasingly scrutinize popular GLP-1 weight loss treatments for causing significant reductions in lean muscle alongside fat loss. Understanding Calocurb … Read more
Rapid weight loss from GLP-1 receptor agonists like Ozempic and Wegovy is driving a surge in demand for body-contouring plastic surgery. Surgeons report an increase in procedures to address “Ozempic face,” “Ozempic breast,” and “Ozempic butt,” as patients seek to correct sagging skin and volume loss that occurs when fat cells shrink faster than the … Read more
Tirzepatide outperforms other FDA-approved GLP-1 medications in achieving weight loss, according to a meta-analysis published in the journal Obesity. Researchers at the University of Georgia found that patients using tirzepatide—marketed as Zepbound and Mounjaro—lost over 20% of their body weight, compared to 15% for semaglutide (Wegovy) and 8% for liraglutide (Saxenda). The findings, based on … Read more
As global temperatures continue to break records, a silent health crisis is brewing at the intersection of climate change, and pharmacology. While most heat safety advice focuses on hydration and shade, a more complex challenge is emerging: the way our modern pharmaceutical landscape interacts with an increasingly hostile thermal environment. For millions of people managing … Read more
The Hidden Link Between Your Pharmacy and the Thermometer For most of us, a heatwave means cranking up the AC and drinking more water. But for millions of people, the danger isn’t just the temperature outside—it’s the chemistry inside. Recent warnings from public health officials, including those in Pima County, have highlighted a “quiet culprit” … Read more
Beyond the Scale: The New Era of GLP-1 Medications For years, the conversation around GLP-1 drugs—such as semaglutide and tirzepatide—has been dominated by a single metric: the number on the scale. While their ability to manage type 2 diabetes and facilitate weight loss is well-documented, we are entering a new phase of understanding. The focus … Read more
The Looming Superbug Crisis: Are We Losing the Fight Against Antibiotic Resistance? The world is facing a growing threat: superbugs. These infection-causing microbes are becoming increasingly resistant to the antibiotics designed to kill them, jeopardizing decades of medical progress. The World Health Organization (WHO) has warned that nearly one in six bacterial infections worldwide showed … Read more
Beyond Weight Loss: Could Diabetes Drugs Quiet the Roar of Addiction? For years, GLP-1 receptor agonists like semaglutide and tirzepatide have been making headlines as revolutionary weight-loss medications. Originally developed to treat type 2 diabetes, their ability to curb appetite and promote weight loss has fueled a surge in popularity. But emerging research suggests these … Read more
The Growing Complexity of Medication and Supplement Interactions: What the Future Holds About one-third of U.S. Adults take a daily multivitamin, often to address nutritional gaps. However, combining multivitamins with prescription and over-the-counter medications can alter how the body absorbs either the supplement or the drug, due to shared absorption pathways and competition for enzymes. … Read more
The Ozempic Effect: What Happens When You Stop, and What’s Next for Weight Management? Millions have turned to GLP-1 medications like Ozempic, Wegovy, and Zepbound for weight loss. But what happens when the injections stop? A new study from the Cleveland Clinic offers a more nuanced picture than previous research, suggesting that significant weight regain … Read more